CAPTUR Canadian Study Testing Targeted Cancer Therapies Based on Tumor Genetic Changes in Adults

What this Trial Is About

Researchers are evaluating targeted therapies for cancer patients whose tumors have specific abnormal gene changes. This study, called CAPTUR, aims to understand how these targeted drugs affect patients and their cancers. It focuses on patients with incurable metastatic solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma who have identified druggable genetic changes in their cancers. The study tests several commercially available targeted drugs matched to the genetic abnormalities found in patients tumors. The treatments include various oral and intravenous medications such as Olaparib, Dasatinib, Nivolumab plus Ipilimumab, and others, each given with specific dosing schedules. The trial is non-randomized and includes groups based on different genetic targets some groups are closed and no longer recruiting. Participants will be monitored over time to assess tumor response, side effects, and progression-free survival. Researchers will measure objective response rates after up to four years. Patients undergo tumor profiling to identify genetic changes and must meet organ function and performance status requirements. Follow-up includes safety assessments and evaluation of treatment effects during the study period.

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)